Ab Trill insider trades: DiaMedica Therapeutics (DMAC) stock purchases
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Ab reports to the SEC
Open-market buys and sales
4 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Nov 25, 2025 | DMAC | ↑ Buy | 1,061,277 | $7.19 | $7.6M | Indirect | Dec 8, 2025 (13d) |
| Aug 27, 2025 | DMAC | ↑ Buy | 1,000,000 | $5.96 | $6.0M | Indirect | Sep 4, 2025 (8d) |
| Jul 23, 2025 | DMAC | ↑ Buy | 1,542,857 | $3.50 | $5.4M | Indirect | Jul 25, 2025 (2d) |
| Jun 28, 2024 | DMAC | ↑ Buy | 1,200,000 | $2.50 | $3.0M | Indirect | Jul 1, 2024 (3d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other DMAC insiders
Open-market trades in the last 12 months
About Ab Trill's insider trades
Ab Trill is a 10% owner of DiaMedica Therapeutics (DMAC). Since Jun 28, 2024, Ab has reported 4 open-market purchases worth $22.0M and no sales on SEC Form 4. In the last 12 months: 1 buy ($7.6M).
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every DMAC insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.